Medline Statistics
Total Valuation
Medline has a market cap or net worth of $56.33 billion. The enterprise value is $67.37 billion.
Important Dates
The last earnings date was Wednesday, February 25, 2026, before market open.
| Earnings Date | Feb 25, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Medline has 1.31 billion shares outstanding. The number of shares has decreased by -95.36% in one year.
| Current Share Class | 811.65M |
| Shares Outstanding | 1.31B |
| Shares Change (YoY) | -95.36% |
| Shares Change (QoQ) | -95.35% |
| Owned by Insiders (%) | 0.74% |
| Owned by Institutions (%) | 35.32% |
| Float | 539.55M |
Valuation Ratios
The trailing PE ratio is 29.97 and the forward PE ratio is 29.18. Medline's PEG ratio is 3.31.
| PE Ratio | 29.97 |
| Forward PE | 29.18 |
| PS Ratio | 1.98 |
| Forward PS | 3.77 |
| PB Ratio | 3.24 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | 44.57 |
| P/OCF Ratio | 32.30 |
| PEG Ratio | 3.31 |
Financial Ratio HistoryEnterprise Valuation
The stock's EV/EBITDA ratio is 21.12, with an EV/FCF ratio of 53.30.
| EV / Earnings | 58.13 |
| EV / Sales | 2.37 |
| EV / EBITDA | 21.12 |
| EV / EBIT | 30.92 |
| EV / FCF | 53.30 |
Financial Position
The company has a current ratio of 4.29, with a Debt / Equity ratio of 0.67.
| Current Ratio | 4.29 |
| Quick Ratio | 2.21 |
| Debt / Equity | 0.67 |
| Debt / EBITDA | 3.92 |
| Debt / FCF | 10.30 |
| Interest Coverage | 2.31 |
Financial Efficiency
Return on equity (ROE) is 6.53% and return on invested capital (ROIC) is 6.44%.
| Return on Equity (ROE) | 6.53% |
| Return on Assets (ROA) | 3.66% |
| Return on Invested Capital (ROIC) | 6.44% |
| Return on Capital Employed (ROCE) | 6.05% |
| Weighted Average Cost of Capital (WACC) | n/a |
| Revenue Per Employee | $631,822 |
| Profits Per Employee | $25,756 |
| Employee Count | 45,000 |
| Asset Turnover | 0.76 |
| Inventory Turnover | 4.53 |
Taxes
In the past 12 months, Medline has paid $91.00 million in taxes.
| Income Tax | 91.00M |
| Effective Tax Rate | 7.29% |
Stock Price Statistics
| Beta (5Y) | n/a |
| 52-Week Price Change | n/a |
| 50-Day Moving Average | 44.56 |
| 200-Day Moving Average | n/a |
| Relative Strength Index (RSI) | 40.13 |
| Average Volume (20 Days) | 5,997,361 |
Short Selling Information
The latest short interest is 7.27 million, so 0.55% of the outstanding shares have been sold short.
| Short Interest | 7.27M |
| Short Previous Month | 6.83M |
| Short % of Shares Out | 0.55% |
| Short % of Float | 1.35% |
| Short Ratio (days to cover) | 2.64 |
Income Statement
In the last 12 months, Medline had revenue of $28.43 billion and earned $1.16 billion in profits. Earnings per share was $1.43.
| Revenue | 28.43B |
| Gross Profit | 7.52B |
| Operating Income | 2.18B |
| Pretax Income | 1.25B |
| Net Income | 1.16B |
| EBITDA | 3.19B |
| EBIT | 2.18B |
| Earnings Per Share (EPS) | $1.43 |
Full Income StatementBalance Sheet
The company has $1.98 billion in cash and $13.01 billion in debt, with a net cash position of -$11.04 billion or -$8.40 per share.
| Cash & Cash Equivalents | 1.98B |
| Total Debt | 13.01B |
| Net Cash | -11.04B |
| Net Cash Per Share | -$8.40 |
| Equity (Book Value) | 19.29B |
| Book Value Per Share | 13.22 |
| Working Capital | 8.19B |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was $1.74 billion and capital expenditures -$480.00 million, giving a free cash flow of $1.26 billion.
| Operating Cash Flow | 1.74B |
| Capital Expenditures | -480.00M |
| Free Cash Flow | 1.26B |
| FCF Per Share | $0.96 |
Full Cash Flow StatementMargins
Gross margin is 26.44%, with operating and profit margins of 7.66% and 4.08%.
| Gross Margin | 26.44% |
| Operating Margin | 7.66% |
| Pretax Margin | 4.39% |
| Profit Margin | 4.08% |
| EBITDA Margin | 11.22% |
| EBIT Margin | 7.66% |
| FCF Margin | 4.45% |
Dividends & Yields
Medline does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | 95.36% |
| Shareholder Yield | 95.36% |
| Earnings Yield | 2.06% |
| FCF Yield | 2.24% |
Analyst Forecast
The average price target for Medline is $50.48, which is 17.72% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $50.48 |
| Price Target Difference | 17.72% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 23 |
| Revenue Growth Forecast (5Y) | n/a |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | |
| Graham Upside | |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Medline has an Altman Z-Score of 2.27 and a Piotroski F-Score of 7. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 2.27 |
| Piotroski F-Score | 7 |
